课题基金 / 基金详情

CYTOKINE-MEDIATED PATHOPHYSIOLOGY IN FANCONI ANEMIA

CYTOKINE-MEDIATED PATHOPHYSIOLOGY IN FANCONI ANEMIA
范可尼贫血中细胞因子介导的病理生理学
批准号:
6526631
负责人:
MING CHEN
金额:
$5.44万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
未结题
起止时间:
2002-08-21 至

项目摘要

项目成果

MING CHEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Fanconi anemia (FA) is an autosomal recessive disorder characterized by cellular hypersensitivity to DNA crosslinking agents such as mitomycin C (MMC) and diepoxybutane (DEB) (Auerbach 1993), bone marrow (BM) failure, diverse congenital anomalies, and a marked increased in the incidence of malignancies. Eight complementation groups (FA-A through FA-H) have been identified. The human genes defected in the FA-C, FA- A FA-G groups were recently cloned. Fancc-deficient mice have been created by targeted mutations of the murine Fancc gene. Cells from France -/- mice showed hypersensitivity to MMC and DEB. Surprisingly, however, no gross hematologic defects or congenital anomalies were detected, although the homozygous mice showed decreased fertility. Evidence has been collected indicating that certain cytokines are involved in Fanconi anemia. TNF-alpha and IFN-gamma are inhibitory cytokines that can induced deregulated. Progenitor growth and apoptosis in Fancc-/- hematopoietic progenitor cells (HPC). FANCC transgene protected HPC FANCC transgene protected HPC from Fas-mediated apoptosis. IL-6, TNF-alpha and IFN-gamma, among others, are known to mediate immune-neuro-endocrine interactions. More recently, multiple endocrine abnormalities were discovered in FA patients, including deficiencies in growth hormone, thyroid and gonads function. We hypothesize that the endocrine abnormalities be due to aberrant response to cytokines, particularly TNF-alpha and IFN-gamma, in the endocrine glands. The proposed project will use Fancc-deficient mice and cell lines derived from endocrine glands, along with certain cytokines, to test this hypothesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology
  • 批准号:
    10445187
  • 项目类别:
  • 资助金额:
    $41.65万
  • 财政年份:
    2022
  • 负责人:
    MING CHEN
  • 依托单位:
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer
  • 批准号:
    10518805
  • 项目类别:
  • 资助金额:
    $38.54万
  • 财政年份:
    2022
  • 负责人:
    MING CHEN
  • 依托单位:
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer
  • 批准号:
    10664011
  • 项目类别:
  • 资助金额:
    $37.77万
  • 财政年份:
    2022
  • 负责人:
    MING CHEN
  • 依托单位:
Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology
  • 批准号:
    10579292
  • 项目类别:
  • 资助金额:
    $40.82万
  • 财政年份:
    2022
  • 负责人:
    MING CHEN
  • 依托单位:
海外基金